The Cyclocapnic Method for Measurement of Chemosensitivity
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
We aim to test our method for measuring chemosensitivity (the ventilatory response to a change in carbon dioxide), which uses sinusoidal carbon dioxide stimuli.
Hypotheses:
- Carbon dioxide sensitivity is dependent on the cycle time over which we administer the gas (frequency).
- Chemoreflex gain decreases as deadspace increases.
| Condition | Intervention | Phase |
|---|---|---|
|
Periodic Breathing Heart Failure |
Other: carbon dioxide |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Basic Science |
| Official Title: | Developing an Improved Measure of Chemosensitivity for the Study of Periodic Breathing in Heart Failure: the Cyclocapnic Method |
- Chemoreflex gain as measured by cyclocapnic method [ Time Frame: every minute ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 45 |
| Study Start Date: | January 2008 |
| Estimated Study Completion Date: | October 2010 |
| Estimated Primary Completion Date: | April 2010 (Final data collection date for primary outcome measure) |
-
Other: carbon dioxide
We will apply a new method for the measurement of chemosensitivity (how sensitive a person is to changes in carbon dioxide), which is one of the principle determinants of whether people with heart failure develop abnormal breathing patterns We have shown in a pilot study that administering sinusoidal patterns of inspired carbon dioxide produces similar sinusoidal responses in ventilation. We aim to test our method for measuring chemosensitivity, which uses sinusoidal carbon dioxide stimuli (similar to those that drive the oscillations in ventilation found in periodic breathing). We aim to show that how the cycle time of carbon dioxide administered affects the resulting ventilatory oscillations and therefore that when measuring the chemoreflex clinically, it is important to deliver carbon dioxide stimuli that replicate the cycle time of oscillations in carbon dioxide seen in periodic breathing (typically approximately one minute).
Eligibility| Ages Eligible for Study: | 18 Years to 80 Years |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Heart failure subjects with stable cardiorespiratory control to be recruited from our institution's specialist heart failure clinic.
- Normal healthy volunteers, with normal systolic function.
Exclusion Criteria:
- We will exclude patients with chronic respiratory disease (every patient will have formal lung function testing on entrance into the study) or unstable coronary artery disease (myocardial infarction or unstable angina within the past 3 months).
- In addition any subjects receiving treatment with morphine and derivatives, theophylline, oxygen, benzodiazepines or acetazolamide will be excluded as these affect chemosensitivity.
Contacts and Locations| Contact: Darrel P Francis, MD | +44 207 594 1093 | darrel.francis@imperial.ac.uk |
| United Kingdom | |
| St Mary's Hospital | Recruiting |
| London, United Kingdom, W2 1LA | |
| Contact: Resham Baruah, MB BS 020 75941027 resham.baruah@imperial.ac.uk | |
| Contact: Darrel P Francis, MD +44 207 594 1093 darrel.francis@imperial.ac.uk | |
| Principal Investigator: | Darrel P Francis, MD | Imperial College London |
More Information
No publications provided
| Responsible Party: | Darrel Francis, Imperial College |
| ClinicalTrials.gov Identifier: | NCT01049256 History of Changes |
| Other Study ID Numbers: | 07/H0712/129 |
| Study First Received: | January 13, 2010 |
| Last Updated: | January 13, 2010 |
| Health Authority: | UK: National research ethics committee |
Keywords provided by Imperial College London:
|
Periodic breathing Heart Failure Chemoreflex Chemosensitivity |
Additional relevant MeSH terms:
|
Respiratory Aspiration Heart Failure Respiration Disorders Respiratory Tract Diseases |
Signs and Symptoms, Respiratory Signs and Symptoms Heart Diseases Cardiovascular Diseases |
ClinicalTrials.gov processed this record on May 22, 2013